Abstract
The CYP3A4*22 and CYP3A5*3 polymorphisms have been associated with decreased tacrolimus (TAC) metabolism and decreased TAC dose requirements in numerous transplant (Tx) populations. The objective of this study was to determine the combined impact of CYP3A4*22 and CYP3A5*3 genotypes on TAC disposition in heart transplant (HTx) recipients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
